echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The magic power of health care - the catalyst for drug release.

    The magic power of health care - the catalyst for drug release.

    • Last Update: 2020-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: The reform of the medical insurance catalogue is a microcosm of China's medical reform, from the annual catalog update to the annual dynamic adjustment, the gradual deepening of the health care reform forced enterprise innovation.
    , the National Health Insurance Administration announced the 2020 National Health Insurance Drug Catalog Adjustment Work Programme, officially launched a new round of national health insurance catalog adjustment work.
    is the 2019 health-care catalog adjustment, in principle, the annual adjustment of the health-care catalog.
    's increasingly frequent changes to the health-care catalog highlight the importance the state attaches to medicines, especially for research and development of innovative drugs that have been hot in recent years.
    in China's drug control, medical insurance as the national macro-control grasping hand, the importance of self-evident.
    And for pharmaceutical companies, including health insurance usually means that sales are on the fast track, and while entry must withstand a drop in prices, the positives of higher sales tend to outweigh the disadvantages of lower prices, and companies can still enjoy full sales growth."
    health insurance strength medical insurance is the core driving factor of drug discharge in China.
    statistics, medical insurance payments accounted for 70% of China's drug sales, self-cost drugs survival soil is very limited.
    To the stone drug Entip (butyl benzene) as an example, in 2005, stone medicine spent 300 million yuan to build a heavy-weight product Enbip, after the market drug sales are less than 30 million yuan / year, which is complicated, and the national health insurance mechanism at that time is not unresponsionable (section II key analysis).
    2009, Stone Pharmaceuticals sold Umbipu to Lenovo Holdings because of uncertainty about its sales prospects.
    same year, Umbipu entered health insurance, which brought a huge turnaround to Umbipu, which sold more than 1 billion yuan in 2012.
    can say that Entip's success is closely related to health care.
    success of domestically produced innovative drugs depends on health insurance.
    is a new drug such as HDAC inhibitors developed by microcore biology.
    after going public in 2014, sales were not good, with Q2 sales up 700 per cent month-on-month in 2017 after being negotiated into health insurance.
    's Alishatan esters and Kanghong Pharmaceuticals' Compaqsip have all seen steady releases since they were included in the national health insurance list.
    but the inclusion of health insurance is not without thresholds, and volume-for-price is the core logic behind it.
    if you want to catch the fast train of health insurance, drug prices are inevitable.
    recently, Haussen Pharmaceuticals' star product Amethini (the world's second third-generation EGFR-TKI) for sprint health insurance, the initiative to reduce the price by 50%, from 19,600 yuan / box to 9800 yuan / box.
    in the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs published by the National Health Insurance Administration in 2019, 97 drugs were negotiated into the list, with an average price reduction of 60.7 percent.
    but Amedini is lucky, thanks to the dynamic adjustment mechanism of the health-care directory.
    Dynamic adjustment mechanism was first proposed in 2017, in the Ministry of Human and Social Affairs issued "on the public consultation to establish and improve the basic medical insurance, work injury insurance and maternity insurance drug catalog dynamic adjustment mechanism of the relevant advice and recommendations", clearly proposed to initially establish a dynamic adjustment mechanism of the drug catalog, the purpose is to timely put more life-saving drugs into health insurance.
    Amethini was approved for listing on March 16, 2020, and was unable to keep up with the current round of health care negotiations, but in the 2020 National Health Insurance Drug Catalog Adjustment Work Programme released by the National Health Insurance Administration on August 18th, Amethini was given a ticket to health insurance from December 31, 2019 to August 17, 2020.
    Since the results of this round of health insurance catalog adjustments are expected to be announced in November or December, if Amethini is successfully included in health insurance, this will mean that domestic new drugs will be included in health insurance within six months of the market, this acceleration for pharmaceutical companies to strengthen independent innovation is undoubtedly a drug.
    contrast, before 2017, due to the slow adjustment of the health insurance catalog, approval time is too long, resulting in a large number of domestic innovative drugs difficult to be included in the health insurance catalog, enterprise innovation momentum is insufficient.
    the development of china's innovative drugs has been stuck in the past, which has nothing to do with the old medical insurance mechanism.
    disadvantages of China's old medical insurance mechanism are mainly reflected in the slow update of the directory and long waiting time.
    Before 2017, China's health insurance catalog underwent only three rounds of adjustment, namely, 2000, 2004 and 2009;
    this has led to a number of domestic innovative drugs have been hovering outside the health insurance directory, relying on out-of-the-way patients to survive.
    about self-costed drugs, we have to mention the proportion of drugs strictly controlled by hospitals, the proportion of drugs further compressed the survival of innovative drugs.
    in 1997, 2000, 2009 and 2015, the central government issued documents calling for the proportion of hospital drugs to be strictly controlled at about 30%.
    cost-effective innovative drugs due to higher prices, the increase in sales will significantly increase the proportion of hospital drugs, vulnerable to hospital focus monitoring, which leads to the development of domestic innovative drugs is limited.
    As in 2018, the National Health planning commission of the Hospital Administration issued "on doing a good job in 17 national health insurance negotiations on the use of anti-cancer drugs", an additional emphasis on 17 successful negotiations of anti-cancer drugs are not limited by the proportion of drugs, the total cost of health care, etc. , from the side reflects the drug proportion of the system of the constraints on innovative drugs.
    of these factors, the proportion of innovative drugs in China's medical insurance catalogue was very low in the past.
    more than 2,000 drugs in the 2009 health insurance directory, with less than 2% of innovative drugs.
    until the national health-care directory is updated again in 2017, a number of innovative drugs from the country's "major new drug creation" program are not included in the national health-care catalog.
    2017, eight years later, the health insurance drug catalog ushered in a new update, this update marks China's health insurance catalog from missing to complete, from immature to mature.
    highlight of this adjustment is to determine the core concept of medical insurance services for technological innovation in the pharmaceutical industry.
    2009 edition of the health care catalog mainly highlights the idea of overall consideration, focusing on the affordability of health insurance funds on the basis of clinical needs, so some expensive innovative drugs "shut out."
    with the development of the times, innovation has become the main theme of China's pharmaceutical industry, the efficacy of good, technical excellence, expensive innovative drugs into health insurance is ripe.
    , experts identified 45 drugs to be negotiated, all high-value, high-value patents, exclusive drugs, and eventually 36 drugs were included through negotiation.
    Q3 sales in 2017 increased by 140% month-on-month after Roche Pharmaceuticals' Beval pearl monoantigen entered health insurance.
    results, the proportion of innovative drugs in the new 2017 version of the health care catalog is close to 10%, a significant increase from the 2% of the 2% of the 2009 edition.
    same time, a class of innovative drugs approved since 2011 are all included in the health insurance list, including siddamine, compassip, ektinib and a range of familiar drugs.
    the proportion of drug use is gradually weakening.
    On January 30, 2019, the General Office of the State Council issued the Opinions on Strengthening the Performance Assessment of Public Hospitals at the Third Level, stressing that for the performance appraisal of hospitals, the proportion of single-drug indicators should not be used for assessment, and that the indicators of rational drug use should be taken into account comprehensively, putting the rationality of prescriptions and the safety of medications first.
    this direction shows the future reform of the country's movement, that is, in the use of drugs, weaken the control of costs, highlighting the effect of the control, to a certain extent, also indirectly encouraged the creation of new drugs.
    the reform of the medical insurance catalogue is a microcosm of China's medical reform, from the annual catalog update to the annual dynamic adjustment, the gradual deepening of health insurance reform forced enterprise innovation.
    is also because of the power of health care and various constraints gradually improved, enterprises have more motivation to focus on innovation, the development of more high-tech, clinical efficacy of new drugs.
    to the future, we would like to see more innovative drugs spring up, constantly stand out, leading the pharmaceutical industry to rapid development.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.